2025-07-24 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided. The report is structured as requested, with key data points first, followed by analysis.

**Johnson & Johnson (JNJ) Stock Analysis**

Johnson & Johnson is a global healthcare company that researches, develops, manufactures, and sells a broad range of products in the healthcare field.

**1. Relative Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 23.71%
*   **VOO (S&P 500) Cumulative Return:** 97.07%
*   **Spread (JNJ - VOO):** -73.4
*   **Spread Range (Max: 20.0, Min: -83.0):**
*   **Relative Spread (9.3):**

**Analysis:** JNJ has significantly underperformed the S&P 500. The spread of -73.4 indicates a considerable performance gap. A relative spread of 9.3 suggests that JNJ's underperformance is near its worst historical levels compared to VOO based on the data provided.

*Alpha, Beta Analysis:*

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 28.0%  | 56.1% | -1.0%  | -0.0  | 335.7  |
| 2016-2018  | 8.0%   | 56.6% | -10.0% | 0.0   | 310.1  |
| 2017-2019  | 18.0%  | 56.6% | -12.0% | 0.7   | 350.5  |
| 2018-2020  | 12.0%  | 59.2% | -8.0%  | 0.3   | 378.2  |
| 2019-2021  | 32.0%  | 59.6% | -16.0% | 0.2   | 411.1  |
| 2020-2022  | 7.0%   | 61.4% | 5.0%   | 0.2   | 424.5  |
| 2021-2023  | -15.0% | 61.4% | -33.0% | 0.4   | 376.6  |
| 2022-2024  | -35.0% | 61.4% | -61.0% | 0.3   | 347.5  |
| 2023-2025  | -4.0%  | 70.1% | -52.0% | 0.2   | 403.5  |

**Analysis:**
*   **CAGR (Compound Annual Growth Rate):** The CAGR varies significantly across different periods, with negative growth in recent years (2021-2025).
*   **MDD (Maximum Drawdown):** The MDD is consistently high, indicating substantial potential losses during downturns.
*   **Alpha:** The Alpha values are largely negative, suggesting JNJ has underperformed relative to its benchmark, especially in recent years.
*   **Beta:** The Beta values are generally low, indicating that JNJ is less volatile than the market.
*   **Cap (B):** The market capitalization has fluctuated, reflecting the changing investor sentiment.

**2. Recent Price Action**

*   **Current Price:** 167.93
*   **Last Market Data:** {'price': 167.67, 'previousClose': 167.93, 'change': -0.15}
*   **5-Day Moving Average:** 164.75
*   **20-Day Moving Average:** 157.33
*   **60-Day Moving Average:** 154.95

**Analysis:** The current price is above all three moving averages, suggesting a short-term upward trend. The slight price decrease compared to the previous close doesn't significantly alter this positive trend, but it is worth noting.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3359 (Low Risk)
*   **RSI:** 76.28 (Overbought)
*   **PPO:** 0.7537
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Spread Change:** 7.1 (+) (Short-term Increase)
*   **Expected Return (%):** -291.8%

**Analysis:**

*   **MRI:** Indicates low market risk overall.
*   **RSI:** Suggests the stock is currently overbought, potentially signaling a pullback.
*   **PPO:** Provides insight into the momentum of the price.
*   **Hybrid Signal:** The signal recommends a cautious buy with 80% cash allocation, given the MRI.
*   **Relative Spread Change:** The recent increase suggests short-term positive momentum compared to the S&P 500.
*   **Expected Return:** The significantly negative expected return is a major red flag, indicating potential underperformance compared to the S&P 500 over a long-term investment horizon.

**4. Recent News & Significant Events**

*   **[2025-07-22]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-20]:** Analysts discussing performance and outlook in the context of industry trends and global economic factors.
*   **[2025-07-23]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-21]:** Market experts highlight both risks and opportunities, advising monitoring of news and company announcements.

**Analysis:** The news indicates that JNJ is experiencing volatility and is subject to significant events. Investors should closely monitor company-specific news and analyst opinions to understand the drivers behind these movements.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2024-07-25 | 1.95 | 22.45 B$   |
| 2024-05-01 | 1.35 | 21.38 B$   |
| 2025-04-23 | 1.35 | 21.38 B$   |

**Analysis:**
*   **EPS (Earnings Per Share):** EPS fluctuates significantly across the quarters.
*   **Revenue:** Revenue is relatively stable but shows slight variations.

**6. Financial Information**

*Revenue and Profitability:*

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |

*Capital and Profitability:*

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-03-31 | $78.11B   | 14.08%  |
| 2024-12-31 | $71.49B   | 4.80%   |
| 2024-09-30 | $70.16B   | 3.84%   |
| 2024-06-30 | $71.54B   | 6.55%   |
| 2024-03-31 | $70.02B   | 4.65%   |

**Analysis:**

*   **Revenue:** Revenue is relatively stable over the past five quarters.
*   **Profit Margin:** Profit margins are consistently high, indicating strong profitability.
*   **Equity:** Equity has increased, suggesting financial stability.
*   **ROE (Return on Equity):** ROE fluctuates, with a significant increase in the most recent quarter.

**7. 종합 Analysis**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500.
*   **Technicals:** Short-term uptrend, but RSI indicates overbought conditions.
*   **Risk:** Low market risk according to MRI.
*   **Cautionary Signals:** Negative expected return, high MDD values, largely negative Alpha values.
*   **Financials:** Strong revenue and profit margins, increasing equity, fluctuating ROE.
*   **News:** Recent news suggests volatility and the need to monitor company-specific developments.

**Conclusion:** JNJ presents a mixed picture. While the company exhibits financial strength in terms of revenue, profit margins, and equity, its underperformance compared to the S&P 500, negative expected return, and overbought RSI raise concerns. Investors should exercise caution and conduct further due diligence before considering an investment in JNJ. The recommendation of a cautious buy with 80% cash allocation seems appropriate in this context.
